While HDAC inhibitors alone have displayed anticancer activities in various cancers, a growing number of studies have demonstrated more efficient and tumor specific anticancer activities of HDAC inhibitors when they are given in combination with other drugs. The gene discussed is HDAC9; the disease is cancer.